GPCR Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Structure Therapeutics Inc (GPCR) following the 2026 Q2 hedge fund 13F filings?

As of today, GPCR has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), GPCR gained +0.8% vs +6.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Structure Therapeutics Inc (GPCR)

197 + Investors. Track Smart Money conviction in GPCR. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — GPCR

Based on 197 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds reduced or closed their GPCR positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

🏔️

At the ownership peak (99% of max)

99% of all-time peak

197 hedge funds hold GPCR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +30% more funds vs a year ago

fund count last 6Q

+45 new funds entered over the past year (+30% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 51% buying

111 buying106 selling

Last quarter: 111 funds bought or added vs 106 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-34 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 37 → 23 → 71 → 37. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

📌

Mixed — 34% long-term, 35% new

■ 34% conviction (2yr+) ■ 31% medium ■ 35% new

Of the 197 current holders: 67 (34%) held >2 years, 62 held 1–2 years, and 68 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💎

Buying through price weakness — shares -8%, value -37%

Value

-36%

-8%

Last quarter: funds added -8% more shares while total portfolio value only changed -37%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

🚀

Acceleration phase — new buyers rushing in

23 → 37 → 23 → 71 → 37 new funds/Q

New funds entering each quarter: 37 → 23 → 71 → 37. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

📊

Mixed cohorts — 37% veterans, 39% new entrants

■ 37% veterans ■ 24% 1-2yr ■ 39% new

Of 207 current holders: 76 (37%) held 2+ years, 50 held 1–2 years, 81 (39%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

🏆

Elite ownership — 43% AUM from top-100 funds

43% from top-100 AUM funds

35 of 194 holders are among the 100 largest funds by AUM, controlling 43% of total institutional value in GPCR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

4.3

out of 10

Moderate Exit Risk

Exit risk score 4.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	197	199	-1.01%
13F Shares	62M	68M	-8.13%
Total Value	$2.91B	$4.60B	-36.77%
New Positions	37	71	-34
Increased Positions	72	54	+18
Closed Positions	39	30	+9
Reduced Positions	62	62	-
Total Calls	6	8	-25.0%
Total Puts	7	5	40.0%
PUT/CALL Ratio	1.17	0.62	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

197

199

-1.01%

13F Shares

62M

68M

-8.13%

Total Value

$2.91B

$4.60B

-36.77%

New Positions

-34

Increased Positions

+18

Closed Positions

Reduced Positions

Total Calls

-25.0%

Total Puts

40.0%

PUT/CALL Ratio

1.17

0.62

Neutral

Institutional Holders (2026 Q2)

197 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in GPCR. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 GPCR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Davern Capital Partners, LP	4.08%	446,059	$23.9M
2	Flax Pond Capital, LLC	1.41%	37,000	$1.8M
3	Buckland Partners Management Co LLC	1.31%	50,000	$2.7M
4	HSG Holding Ltd	1.19%	266,062	$14.3M
5	Platinum Investment Management Ltd	1.19%	90,363	$4.8M
6	Siren, L.L.C.	0.95%	872,967	$46.9M
7	Rhenman & Partners Asset Management AB	0.74%	145,100	$7.8M
8	Jones Hill Capital LP	0.46%	40,567	$2.2M
9	CenterBook Partners LP	0.39%	148,030	$7.9M
10	ArrowMark Colorado Holdings LLC	0.34%	150,579	$8.1M
11	DCF Advisers, LLC	0.30%	32,100	$1.7M
12	Capitolis Liquid Global Markets LLC	0.24%	1,041,100	$55.9M
13	TrueMark Investments, LLC	0.23%	33,600	$1.8M
14	Soleus Capital Management, L.P.	0.20%	107,000	$5.7M
15	SmartHarvest Portfolios, LLC	0.17%	9,928	$533K
16	Peregrine Capital Management LLC	0.16%	92,229	$4.9M
17	Private Capital Advisors, Inc.	0.14%	29,760	$1.6M
18	Fox Run Management, L.L.C.	0.10%	10,776	$578K
19	Virtus Investment Advisers, LLC	0.10%	7,622	$409K
20	Gilbert & Cook, Inc.	0.06%	9,167	$492K
21	Arrowpoint Investment Partners (Singapore) Pte. Ltd.	0.05%	4,645	$249K
22	ANTIPODES PARTNERS Ltd	0.05%	51,262	$2.8M
23	SEB Asset Management AB	0.05%	245,043	$13.2M
24	Aberdeen Group plc	0.05%	639,915	$34.3M
25	Principal Financial Group Inc	0.05%	1,752,753	$94.1M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Structure Therapeutics Inc (GPCR)

What does the Smart Money Trend signal show for GPCR?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their GPCR positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for GPCR?

Slight buying edge — 51% buying: Last quarter: 111 funds bought or added vs 106 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for GPCR holders?

Elite ownership — 43% AUM from top-100 funds: 35 of 194 holders are among the 100 largest funds by AUM, controlling 43% of total institutional value in GPCR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held GPCR?

Mixed — 34% long-term, 35% new: Of the 197 current holders: 67 (34%) held >2 years, 62 held 1–2 years, and 68 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Structure Therapeutics Inc (GPCR) following the 2026 Q2 hedge fund 13F filings?

As of today, GPCR has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), GPCR has gained +0.8% vs +6.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Structure Therapeutics Inc (GPCR)

Smart Money Signals — GPCR

Selling streak — 1 quarter in a row

At the ownership peak (99% of max)

Fast accumulation — +30% more funds vs a year ago

Slight buying edge — 51% buying

Fewer new buyers each quarter (-34 vs last Q)

Mixed — 34% long-term, 35% new

Buying through price weakness — shares -8%, value -37%

Acceleration phase — new buyers rushing in

Mixed cohorts — 37% veterans, 39% new entrants

Elite ownership — 43% AUM from top-100 funds

Institutional Sentiment Summary — GPCR

Hedge Fund Ownership: GPCR

Market Analysis: GPCR

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: GPCR

Is It Too Late to Buy Structure Therapeutics Inc (GPCR) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: GPCR

Statistics: GPCR

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Structure Therapeutics Inc (GPCR)

Welcome to 13Foresight!